On August 26, 2024, Stephen Betz, Chief Scientific Officer of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), sold 3,000 shares of the company at a price of $53.19 per share. The transaction was documented in a recent SEC filing. Following this sale, the insider now owns 69,611 shares of Crinetics Pharmaceuticals Inc. Crinetics Pharmaceuticals Inc. is a clinical-stage […]